ストックスクリーナーアプリを入手
58.62
1.43%
-0.85
アフターアワーズ：
58.72
0.10
+0.17%
前日終値:
$59.47
開ける：
$59.79
24時間の取引高:
8.06M
Relative Volume:
0.61
時価総額：
$119.69B
収益：
$48.19B
当期純損益:
$7.06B
株価収益率:
16.95
EPS:
3.4587
ネットキャッシュフロー:
$12.85B
1週間 パフォーマンス:
-1.64%
1か月 パフォーマンス:
-2.51%
6か月 パフォーマンス:
+33.35%
1年 パフォーマンス:
+16.17%
1日の値動き範囲:
$58.46
$59.80
1週間の範囲:
$57.65
$59.80
52週間の値動き範囲:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.62 | 119.69B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
939.47 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.94 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.03 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.42 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | アップグレード | UBS | Neutral → Buy |
| 2025-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-12-12 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 開始されました | Piper Sandler | Overweight |
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Which Dividend Pharma Stock Should a Value Investor Choose Today? - The Motley Fool
Bartlett & CO. Wealth Management LLC Has $7.26 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock? - TradingView — Track All Markets
Assessing Bristol Myers Squibb (BMY) Valuation After Camzyos Data And T Cell Engager Collaboration News - Yahoo Finance
BMS and Oxford BioTherapeutics join forces in TCE discovery pact - Pharmaceutical Technology
Bristol Myers Squibb stock (US1101221083): Is its oncology pipeline strong enough to unlock new upsi - AD HOC NEWS
Bristol Myers Squibb Cancer Alliance Adds Weight To Valuation Debate - Yahoo Finance
F&V Capital Management, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Bristol-Myers Squibb Company (BMY) stock price, news, quote and history - Yahoo Finance Singapore
Bristol-Myers Likely to Get Desired Court in Paxton Plavix Suit - Bloomberg Law News
Oxford BioTherapeutics Partners with Bristol Myers Squibb for Next-Gen T-Cell Therapies - National Today
Bristol-Myers Squibb Earnings Preview: What to Expect - Yahoo Finance
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours - Yahoo Finance
Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst - Insider Monkey
MFS Blended Research Core Equity Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst - Benzinga
Bristol-Myers Squibb: Vestmo Stock of the Week - Barron's
Cantor Fitzgerald raises Bristol-Myers Squibb stock price target to $54 - Investing.com
Guggenheim reiterates Bristol-Myers Squibb stock rating at Buy - Investing.com
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline - Reuters
Bristol-Myers Squibb Company (BRM.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol-Myers Squibb Company (BMY) latest stock news and headlines - Yahoo Finance UK
Bristol-Myers Squibb Company (BMY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scotiabank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $60 - 富途牛牛
Pleural Diseases Market Set to Boom Rapidly by 2033 |Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc - openpr.com
Nathan Pennell: "Global and Local" Model Takes Focus During BMS Japan Visit - Oncodaily
Case-By-Case Guide As Justices Eye Landmark Pharma Law - Law360
Trust Co. of Toledo NA OH Sells 55,523 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Element Squared LLC Acquires Shares of 48,420 Bristol Myers Squibb Company $BMY - MarketBeat
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock - Investing.com Australia
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - Yahoo Finance UK
BRISTOL-MYERS SQUIBB CO (BMYS.VI) Q1 FY2025 earnings call transcript - Yahoo Finance
Growth and Income Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term - Yahoo Finance
BRISTOL-MYERS SQUIBB CO (BMYS.VI) Q2 FY2025 earnings call transcript - Yahoo Finance
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock By Investing.com - Investing.com South Africa
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co (BMY) Shares Down 3.58% on Apr 2 - GuruFocus
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review - Ad Age
Bristol Myers Squibb Cancer Pact And Equity Push Raise Valuation Questions - simplywall.st
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.58% on Apr 2: What Signal Does It Send? - TradingKey
Bristol-Myers Squibb (BMY) Announces Positive Data from the Phase 3 SCOUT-HCM Trial of Camzyos - Insider Monkey
Ritter Alpha, LP's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tema Etfs LLC Has $6.89 Million Holdings in Bristol Myers Squibb Company $BMY - marketbeat.com
20,914 Shares in Bristol Myers Squibb Company $BMY Acquired by J. Safra Sarasin Holding AG - MarketBeat
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
0.21%
大文字化:
|
ボリューム (24 時間):